Varex Imaging Corporation logo
Varex Imaging Corporation VREX
$ 11.61 -0.34%

Quarterly report 2025-Q4
added 02-10-2026

report update icon

Varex Imaging Corporation Financial Ratios 2011-2026 | VREX

Annual Financial Ratios Varex Imaging Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-7.1 -11.8 15.9 29.3 71.3 -10.7 72.3 34.4 24.9 - - - - - -

P/S

0.6 0.7 0.8 1.0 1.5 0.8 1.4 1.2 1.8 - - - - - -

EPS

-1.7 -1.2 1.2 0.8 0.4 -1.5 0.4 0.7 1.4 1.8 2.1 - - - -

EV (Enterprise Value)

978 M 1.08 B 1.27 B 1.44 B 1.75 B 1.19 B 1.69 B 1.46 B 1.86 B 59.9 M 67.4 M 73.8 M - - -

EBITDA per Share

-0.11 1.31 2.4 2.69 2.41 -0.29 2.2 2.26 2.92 - - - - - -

EV/EBITDA

18.2 101.7 17.1 14.5 15.0 - - - - - -

PEG

0.03 0.05 -0.08 -0.14 - 0.02 -1.65 -0.73 -1.59 - - - - - -

P/B

1.0 1.1 1.3 1.6 2.5 1.3 2.5 2.2 3.4 - - - - - -

P/CF

12.0 12.2 6.9 52.6 13.4 47.0 21.5 14.6 23.6 - - - - - -

ROE %

-14.88 -9.22 8.23 5.54 3.50 -12.43 3.48 6.45 13.61 - - - - - -

ROA %

-6.35 -4.02 3.79 2.56 1.52 -5.08 1.49 2.78 4.96 - - - - - -

ROCE %

-5.88 6.07 13.38 16.13 14.92 -7.23 5.29 5.32 9.42 - - - - - -

Current Ratio

1.8 1.8 1.9 1.9 1.8 1.7 2.5 3.0 3.3 - - - - - -

DSO

67.9 72.3 68.8 69.8 62.3 65.5 65.9 72.7 85.5 - - - - - -

DIO

185.8 178.6 175.7 167.3 165.8 173.2 172.9 165.2 192.5 - - - - - -

DPO

42.5 40.8 43.2 43.4 44.0 43.7 40.5 46.6 48.4 - - - - - -

Operating Cycle

253.7 250.9 244.5 237.1 228.1 238.6 238.9 237.9 278.1 - - - - - -

Cash Conversion Cycle

211.2 210.1 201.3 193.7 184.1 195.0 198.3 191.3 229.7 - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Varex Imaging Corporation

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

0.06 - -2.15 0.17 -0.01 - 0.03 0.03 -0.01 - 0.23 0.1 0.08 - 0.21 0.19 0.04 - 0.31 0.08 -0.03 -0.81 -0.73 -0.05 - 0.19 -0.04 0.15 0.08 0.73 0.1 0.08 0.3 0.98 0.28 0.3 0.3 1.24 0.47 0.39 - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

0.5 - -1.92 0.56 0.42 - 0.27 0.28 0.23 - 0.68 0.47 0.44 - 0.67 0.76 0.48 - 0.92 0.51 0.25 -0.09 -0.39 0.15 - 1.26 0.49 0.47 0.53 1.43 0.47 0.53 0.49 1.81 0.64 0.49 0.58 2.23 0.88 0.58 - - - - - - - - - - - - - - - - - - - -

ROE %

-37.40 -18.37 -18.13 1.67 0.66 0.39 2.06 3.49 4.02 3.03 4.58 4.47 5.17 3.31 5.85 6.84 6.01 2.90 -4.08 -12.89 -13.95 -12.00 -3.36 2.59 2.65 3.35 8.14 9.35 8.75 10.89 14.15 16.05 18.33 17.49 16.62 17.17 16.30 14.30 5.46 2.11 - - - - - - - - - - - - - - - - - - - -

ROA %

-15.88 -7.81 -7.70 0.71 0.31 0.18 0.93 1.57 1.81 1.36 1.36 1.27 1.59 1.45 1.82 2.86 2.46 1.18 -1.58 -5.10 -5.54 -4.70 -1.23 1.12 1.14 1.44 3.51 4.03 3.77 4.58 5.33 5.97 6.75 7.36 11.30 13.11 13.80 12.08 4.61 1.78 - - - - - - - - - - - - - - - - - - - -

ROCE %

-28.20 -11.66 -10.09 9.21 6.50 3.60 8.04 10.91 12.53 9.84 14.20 14.11 16.36 12.29 17.74 18.84 16.94 9.75 5.14 -6.24 -9.20 -3.60 7.64 14.61 10.92 13.36 15.67 16.35 15.53 16.51 22.64 25.02 26.17 26.10 25.51 26.81 26.76 23.40 8.94 3.54 - - - - - - - - - - - - - - - - - - - -

Current Ratio

1.8 1.8 1.8 1.7 1.7 1.8 1.9 1.9 1.9 1.9 1.8 1.8 1.8 1.9 - 1.8 1.8 1.8 1.7 1.8 1.8 1.7 1.7 1.7 - 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.7 1.6 1.6 1.6 8.0 7.2 7.2 7.2 - - - - - - - - - - - - - - - - - - - -

DSO

66.0 - 63.5 60.8 67.5 - 66.2 64.4 72.8 - 63.4 63.5 73.5 - 32.8 59.8 64.8 - 65.6 62.4 56.2 19.9 66.0 28.7 - 22.2 65.4 63.9 70.6 24.7 73.5 64.4 76.0 30.9 87.8 81.1 67.7 24.9 73.7 35.4 - - - - - - - - - - - - - - - - - - - -

DIO

204.8 - 196.4 189.1 189.3 - 182.2 187.1 194.7 - 178.1 185.1 199.9 - 87.0 163.9 160.8 - 155.7 162.2 177.6 58.6 171.2 89.0 - 57.6 166.5 175.3 178.5 57.4 167.3 167.2 190.8 69.8 193.5 205.8 185.7 67.0 203.8 91.3 - - - - - - - - - - - - - - - - - - - -

DPO

48.6 - 47.6 45.7 43.3 - 44.6 46.5 47.5 - 43.5 47.1 52.7 - 25.5 47.7 44.4 - 41.6 43.4 48.0 15.7 45.9 23.9 - 13.5 39.0 43.0 47.9 16.2 47.2 43.4 46.6 17.5 48.6 46.3 37.8 14.2 43.2 19.4 - - - - - - - - - - - - - - - - - - - -

Operating Cycle

270.7 - 260.0 249.9 256.8 - 248.4 251.5 267.5 - 241.5 248.6 273.4 - 119.9 223.7 225.7 - 221.4 224.6 233.8 78.5 237.2 117.7 - 79.9 231.9 239.2 249.1 82.1 240.8 231.6 266.9 100.7 281.2 286.9 253.5 91.9 277.4 126.8 - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

222.2 - 212.3 204.3 213.5 - 203.8 205.0 220.0 - 197.9 201.5 220.7 - 94.4 176.0 181.3 - 179.8 181.2 185.9 62.8 191.3 93.8 - 66.3 192.9 196.2 201.2 65.9 193.7 188.2 220.2 83.2 232.6 240.6 215.7 77.7 234.2 107.4 - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Varex Imaging Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 13.17 0.46 % $ 1.78 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 10.8 4.05 % $ 387 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Electromed Electromed
ELMD
$ 25.6 -0.43 % $ 216 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.47 4.52 % $ 130 M franceFrance
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
$ 2.12 3.92 % $ 1.29 M usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
$ 56.7 1.0 % $ 1.67 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 61.0 1.5 % $ 3.33 B britainBritain
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 11.37 1.7 % $ 322 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.61 0.36 % $ 38 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 1.03 - $ 17.4 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 15.65 3.92 % $ 367 M usaUSA
Butterfly Network Butterfly Network
BFLY
$ 5.4 12.97 % $ 1.14 B usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Sintx Technologies Sintx Technologies
SINT
$ 2.41 14.22 % $ 6.68 M usaUSA
Globus Medical Globus Medical
GMED
$ 91.34 1.29 % $ 12.4 B usaUSA
TransMedics Group TransMedics Group
TMDX
$ 100.01 -0.77 % $ 3.4 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 36.8 0.38 % $ 1.14 B usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 84.03 -5.06 % $ 2.92 B usaUSA
Stryker Corporation Stryker Corporation
SYK
$ 294.73 -6.47 % $ 113 B usaUSA
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 83.98 0.57 % $ 49.1 B usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 19.41 -0.61 % $ 1.32 B usaUSA
LENSAR LENSAR
LNSR
$ 5.61 7.27 % $ 67.1 M usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.35 5.47 % $ 54.9 M usaUSA
MiMedx Group MiMedx Group
MDXG
$ 3.68 9.52 % $ 544 M usaUSA
Myomo Myomo
MYO
$ 0.9 4.16 % $ 37.7 M usaUSA